KROS
Keros Therapeutics, Inc.
Next earnings Aug 4, 2026 (before open) · consensus $-1.37 EPS, $823K rev
Last earnings -8.3% on 2026-05-14
$10.99
▲ +5.57%$10.99▼ -20.13%
over 1Y
L $9.91EODHDH $21.84
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+5.6%
1W+0.1%
1M-2.8%
3M+3.6%
YTD-40.7%
1Y-20.1%
Buy
Conviction
Horizon
Medium (3–12mo)
Street · 14 analysts
Buy
Revenue grew 6775.0% YoY.
Revenue (FY2025) $244M · FY2025
The read
Quality fundamentals and an attractive price line up (~695% below fair value) — the rarer case where both the business and the entry look good.
Keros Therapeutics, Inc. shows $244M in FY2025 revenue (+6775.0% YoY), a 35.7% net margin, and 28.7% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $20.1M | $0.00 | $151K | $3.55M | $244M |
| Gross profit | — | — | — | — | — |
| Operating income | -$56.4M | -$115M | -$170M | -$211M | $67.6M |
| Net income | -$58.7M | -$105M | -$153M | -$187M | $87.0M |
| Diluted EPS | -$2.52 | -$4.15 | -$5.20 | -$5.00 | $2.30 |
| Net margin | -292.3% | — | -101319.2% | -5277.5% | 35.7% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value-$70.7M
EV / EBITDA—
EV / Sales-0.3
EV / FCF-0.7
P / FCF2.0
PEG (trailing)0.03
Earnings yield40.2%
FCF yield48.9%
Quality & risk
ROIC (est.)17.6%
Free cash flow$106M
Total debt—
Net cash$287M
Altman Z-Score4.16 safe
Piotroski F-Score6/7
Capital returns
Buyback yield83.3%
Dividend yield (est.)—
Shareholder yield83.3%
Shares Δ YoY-51.4%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-232026-06-25open ↗4Period ending 2026-06-152026-06-17open ↗4Period ending 2026-06-112026-06-15open ↗144Filing2026-06-11open ↗4Period ending 2026-06-042026-06-08open ↗4Period ending 2026-06-042026-06-08open ↗4Period ending 2026-06-032026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-032026-06-05open ↗4Period ending 2026-06-032026-06-05open ↗4Period ending 2026-06-032026-06-05open ↗4Period ending 2026-06-032026-06-05open ↗
Frequently asked
- Is Keros Therapeutics, Inc. (KROS) a buy?
- KROS currently carries a Buy rating with 5/5 conviction, derived from its latest SEC filings. Revenue grew 6775.0% YoY.
- What is KROS's fair value?
- A Modified-Graham model based on KROS's SEC fundamentals estimates a fair value of about $87.40. It is an estimate from reported earnings, not a price target.
- Is KROS overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, KROS currently appears undervalued relative to its SEC-grounded earnings power.
- What is Keros Therapeutics, Inc.'s quality score?
- KROS scores 92.29411764705881/100 (grade A+) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001664710, latest 10-Q filed 2026-05-14) · EODHD · as of 6/26/2026, 7:09:31 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.